ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.66 USD
-0.15 (-5.34%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
ADC Therapeutics SA [ADCT]
Reports for Purchase
Showing records 1 - 20 ( 57 total )
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
AACR Preclinical Data; LOTIS-7 Update; 4Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Data Catalysts Abound; Several Presentations Slated for AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
We See Greater Potential For ZYNLONTA in 2L DLBCL; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
We Eagerly Await Additional LOTIS-7 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
3Q23 Financials Reported; Lowering PT to $3 on Sales Trajectory Revision
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Revising Our 2023 ZYNLONTA Sales Forecast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Updated Safety Run-in LOTIS-5 Data at SOHO; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
LOTIS-9 Discountination Does Not Alter Our Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Long-Term LOTIS-2 Results Presented; Corporate Strategy Adjusted; 1Q23 Financials; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Initial ADCT-602 Results Presented; Zynlonta Approved by EC; Modulating PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
LOTIS-5 Safety Lead-in Demonstrates Encouraging Response Rate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
CHMP Issues Positive Opinion for ZYNLONTA; Increasing PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Polivy Front-Line Entry May Help ZYNLONTA; 2Q22 Results; Lowering PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
License Inked With Sobi For ZYNLONTA in Europe; Lowering PT to $44
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Phase 2 Cami Results Sets Stage for BLA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
CEO Transition Does Not Impact Our Thesis; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
ZYNLONTA European Launch This Year; 2021 Financials; Modulating PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: ADC Therapeutics SA
Industry: Medical - Biomedical and Genetics
ZYNLONTA Agreement Inked With Mitsubishi Tanabe for Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R